Source-grounded facts extracted from NRX Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
NRX Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the Investors valued at approximately $6.28 million (effective 2023-06-06).
“On June 6, 2023, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with the purchasers signatory thereto (the “Investors”), providing for the issuance and sale of 9,670,002 shares of the Company’s common stock”
NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“April 18, 2023, the Company received a written notification (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Registrant was not in compliance with Nasdaq Listing Rule 5450(a)(1), as the Registrant’s closing bid price for its common stock was below $1.00 per share for the last thirty (30) consecutive business days. Nasdaq’s notice has no immediate effect on the listing of the common stock on The Nasdaq Global Market and, at this time, the common stock will continue to trade on The Nasdaq Global Market under the symbol “NRXP”. Pursuant to Nasdaq Listing Rule 5810(c)”
NRX Pharmaceuticals, Inc. reported financial results for full year and fourth quarter ended December 31, 2022.
“On March 30, 2023, the Company announced its financial results for the full year and fourth quarter ended December 31, 2022.”
NRX Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the purchasers listed on the signature page thereto (the "Investors") valued at $0.75 per share (effective 2023-03-08).
“On March 8, 2023, NRx Pharmaceuticals, Inc. (the "Company," "us" or "we") entered into a securities purchase agreement (the "Securities Purchase Agreement") with the purchasers listed on the signature page thereto (the "Investors"), providing for the issuance and sale of 3,766,666 shares of the Company's common stock”
NRX Pharmaceuticals, Inc. shareholders approved Approval of issuance of shares of common stock to Streeterville Capital, LLC in accordance with Nasdaq Listing Rule 5635(d) at the 2023-03-03 meeting.
“The Company’s stockholders approved approve the issuance of shares of common stock to Streeterville Capital, LLC in accordance with Nasdaq Listing Rule 5635(d). The results of the voting were as follows: Votes For Votes Against Abstentions 38,338,555 311,870 373,843”
Robert Besthof resigned as Head of Operations and Chief Commercial Officer at NRX Pharmaceuticals, Inc..
“On February 16, 2023, Mr. Robert Besthof, NRx Pharmaceuticals, Inc.’s (the “Company”) Head of Operations and Chief Commercial Officer, notified the Company of his resignation.”
NRX Pharmaceuticals, Inc. reported financial results for third quarter 2022.
“On November 14, 2022, the Company announced its financial results for the third quarter 2022.”
NRX Pharmaceuticals, Inc. entered into APA with Relief Therapeutics Holding AG and Relief Therapeutics International valued at up to an aggregate amount of $13.0 million (effective 2022-11-12).
“On November 12, 2022, NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) entered into a Settlement Agreement and Asset Purchase Agreement (“APA”) with Relief Therapeutics Holding AG and Relief Therapeutics International (the “Relief Parties”) to settle the outstanding lawsuit with respect to the Binding Collaboration Agreement dated September 18, 2020 between the Company and the Relief Parties (the “Collaboration Agreement”).”
NRX Pharmaceuticals, Inc. incurred loan of $11,020,000 million with Streeterville Capital, LLC at 9% interest rate maturing 18 months from the issuance date.
“On November 4, 2022, NRx Pharmaceuticals, Inc. (“NRx” or the “Company”) entered into a Securities Purchase Agreement (“SPA”) with Streeterville Capital, LLC, a Utah limited liability company (“Lender”), and, pursuant to the SPA, issued to the Lender an unsecured promissory note with a face amount of $11,020,000 million (the “Note”) before an original issue discount of $1,000,000, which was deducted from the proceeds of the Note.”
Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary at NRX Pharmaceuticals, Inc..
“On July 22, 2022, Ms. Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary of NRx Pharmaceuticals, Inc. (the “Company”), effective immediately.”
Robert Besthof changed role as Head of Operations and Chief Commercial Officer at NRX Pharmaceuticals, Inc..
“With the appointment of Mr. Willard as the new CEO, the interim CEO, Mr. Robert Besthof, has agreed to remain with the Company and will resume his responsibilities as Head of Operations Officer and Chief Commercial Officer for the Company.”
Stephen Willard was appointed as Chief Executive Officer and Director at NRX Pharmaceuticals, Inc..
“On July 12, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “Company”) appointed Stephen Willard, 61, to serve as Chief Executive Officer (“CEO”) of the Company and a member of the Board of Directors, with immediate effect.”
Dr. Seth Van Voorhees was appointed as Chief Financial Officer and Treasurer at NRX Pharmaceuticals, Inc..
“On June 6, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Dr. Seth Van Voorhees, 61, to serve as Chief Financial Officer (“CFO”) and Treasurer of the Company, effective June 13, 2022.”
Ira Strassberg resigned as Chief Financial Officer and Treasurer at NRX Pharmaceuticals, Inc..
“On May 19, 2022, Mr. Ira Strassberg tendered his resignation as Chief Financial Officer and Treasurer of the Company effective July 18, 2022.”
Ira Strassberg was appointed as Chief Financial Officer and Treasurer at NRX Pharmaceuticals, Inc..
“On March 15, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “Company”) appointed Mr. Ira Strassberg, 55, to serve as Chief Financial Officer (CFO) and Treasurer of the Company effective immediately.”
Robert Besthof was appointed as Interim Chief Executive Officer at NRX Pharmaceuticals, Inc..
“On March 8, 2022, the Board appointed Mr. Robert Besthof to serve as Interim Chief Executive Officer of the Company during the transition.”
Jonathan Javitt retired as Chief Scientist at NRX Pharmaceuticals, Inc..
“On March 8, 2022, Dr. Jonathan Javitt, MD, MPH, announced his retirement from his position as Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”), effective immediately.”
Gen. H.R. McMaster departed as director at NRX Pharmaceuticals, Inc..
“On February 7, 2022, one of the Company’s directors Gen. H.R. McMaster informed the Board that he would be retiring from the Board with effect from the next Annual Meeting of Shareholders (the “Annual Meeting”).”
Alessandra Daigneault was appointed as Acting Treasurer at NRX Pharmaceuticals, Inc..
“Alessandra Daigneault, the Company’s General Counsel and Corporate Secretary will serve as Acting Treasurer.”
James Brandon was appointed as Comptroller and Acting Chief Financial Officer at NRX Pharmaceuticals, Inc..
“James Brandon, who served as Comptroller and Acting CFO for NeuroRx, Inc. since inception through 2020, will resume those duties”
William Fricker departed as Chief Financial Officer (CFO) and Treasurer at NRX Pharmaceuticals, Inc..
“announced the upcoming departure of William Fricker, Chief Financial Officer (CFO) and Treasurer. Mr. Fricker’s last day with the Company will be August 30, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.